Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVB-620 in primary breast cancer surgery
NCT03113825Phase 2Completed
- Sponsor
- Avelas Biosciences, Inc.
- Start
- Jul 2017
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Pegloprastide in breast cancer, sponsored by Avelas Biosciences, Inc. Primary endpoint: Accuracy of AVB-620 imaging data to distinguish between malignant and nonmalignant tissues at 1 month. Started Jul 2017; status: completed.
02
Drugs
Pegloprastide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03113825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113825.